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Abstract: Sequence variations in genes that code for proteins involved in homeostatic processes within tendons may 
influence tendon mechanical properties. Since variants of the four genes COL5A1, TNC, MMP3 and GDF5 have been 
implicated in the aetiopathogenesis of tendinopathies, which is ultimately characterised by abnormal structural and 
regulatory processes, sequence variations in these four genes may also influence how the tendon functions mechanically, 
even in the absence of tendinopathy. For example, two reports of association between variation in the COL5A1 gene and 
measures of flexibility complement reported associations between genotype and incidence of tendinopathy. Non-genetic 
factors such as age, body mass and physical activity status influence risk of tendon injury and physical performance 
potential independently from genomics, and also in gene-environment interactions. However, these non-genetic factors 
are often not considered in genetic association studies, probably due to their retrospective nature. Further research 
examining COL5A1, TNC, MMP3 and GDF5, as well as other genes that may influence the maintenance of tendon 
homeostasis such as COL1A1 which regulates the production of collagen type 1, the most abundant structural component 
of tendon is encouraged. Establishing the genetic basis of tendon properties in asymptomatic populations may advance 
understanding of some aspects relevant to physical performance and of the aetiology of tendinopathies. To improve 
understanding, accurate and reproducible assessments of tendon properties are required. However, no valid and reliable 
assessments of tendon properties, such as those involving in vivo ultrasound imaging techniques, have yet been applied to 
genetic association studies in humans. 
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1. TENDON PROPERTIES 
 Historically, tendons were considered bands of 
connective tissue with relatively no dynamic function [1-2]. 
More recently, numerous studies have shown that tendons 
provide an integral interface for transmission of forces from 
muscle to the bone in order to produce moments about joints, 
hence the mechanical properties of tendons determine the 
degree of joint motion in direct response to these forces [3]. 
From a biomechanical standpoint, external loads that act on 
the body are resisted by internal structures such as tendons, 
which undergo deformation. The degree of deformation or 
strain produced is related to the stress caused by these 
external loads and the material that it acts upon. Thus, 
knowledge of the mechanical properties of musculoskeletal 
tissues, including tendons, can assist in understanding injury 
risk and physical performance capabilities. The primary 
mechanical properties of relevance to human physical 
performance [4-8] include stiffness (the tendon force-
displacement relationship) and the elastic modulus (the slope 
of the stress-strain curve in the elastic deformation region). 
 A biomechanical viewpoint only provides us with an 
analysis of forces and their ‘action’ or ‘effects’ on such 
structures and their function. To understand the mechanical 
properties of tendons, one needs to explore its structure - i.e.  
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both its global characteristic dimensions (e.g. cross-sectional 
area and length) as well as its internal structures (e.g. cross-
link density) - and its dynamic function in greater detail, by 
examining its biochemical components. The structure or 
morphology of tendon, and thus its function, is controlled by 
cells called tenocytes that maintain the extracellular matrix 
(ECM) [9] and ultimately its material and mechanical 
properties. 
 The tenocytes ‘sense’ and respond to mechanical loads 
deriving from external forces. The sensitivity of this 
response has recently been found to be mediated by a 
‘mechanostat’ set point, in vitro [9]. This preset threshold is 
governed by complex interactions between the cell’s 
cytoskeleton and the ECM [9-13], ultimately giving rise to 
gene regulation and control over the tendon’s structure and 
function at a molecular level. Fundamentally, the expression 
of functional gene products or proteins is regulated, which 
provides the basis for maintenance and changes in structure 
and function. Mechanical signalling from external loads [9, 
11, 12, 14, 15] causes gene expression of various proteins 
involved in tendon homeostasis to vary greatly between and 
within animal and human populations. However, even if 
mechanical loading is controlled, the abundance of various 
proteins can still vary. This is where genetic variation is 
likely to influence observed/measurable differences in 
protein content, and thus material and mechanical properties. 
 Tendon pathologies or tendinopathies (including 
tendinosis and tendinitis) are primarily degenerative 
conditions that may or may not be associated with signs of 
inflammation [16-17]. Since research in this area is relatively 
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extensive, reference to research studies on tendinopathies 
will form a small element of this review, For example, recent 
work has associated tendinopathies with genetic variants in 
proteins that serve important structural and functional roles 
in tendon. However, in this review, attempts will also be 
made to consider how those same molecular characteristics 
may influence tendon mechanical properties per se. That is 
to say, the same gene variants and differential gene 
expression of these same proteins may directly influence 
tendon mechanical properties either with or quite separately 
from their influence on incidence of injury. Indeed, there is 
conflicting evidence from some pathological studies 
regarding mechanical properties. Some studies report no 
significant difference in mechanical properties in patients 
with tendon pathology from healthy subjects [18-22], but 
other studies reporting significant weakening of material and 
altered mechanical tendon properties, with both increased 
stiffness [23] and decreased stiffness [24-26] observed in 
patients. The inconsistent results regarding human in vivo 
mechanical properties between studies on tendon pathology 
may be a consequence of different tendon types under 
investigation, (total collagen levels vary between tendon 
types in normal tendons [27, 28]) as well as varying subject 
age and sex. The latter two factors of age [29-32] and sex 
[33-35] are frequently reported to be highly influential on 
tendon material and mechanical properties. 
 Seven genes will be discussed in this review. The seven 
genes and how they relate to the five tendon proteins they 
produce are shown in Table 1. Four of the genes listed in 
Table 1 (COL5A1, TNC, MMP3, GDF5) have genetic 
variants reported in recent tendinopathy studies that may 
predispose individuals to such conditions [36-41]. In fact, all 
the genes that contain sequence variants shown to be 
associated with tendon pathology to date, encode for proteins 
directly involved in biological processes within tendons. Fig. 
(1) shows the key structural proteins found in tendon, 
including those associated with tendon pathologies or 
musculotendinous range of motion. Therefore, these genes 
can also be considered as candidate genes for association 
with fundamental tendon properties. Two studies have 
already reported an association between a polymorphism in 
one of these genes and measures of musculotendinous range 
of motion in humans [41, 42]. Table 2 summarises the 
genetic association studies that have identified a 
polymorphic association with tendon pathologies/musculo-
tendinous range of motion in humans. In addition to the four 
genes associated with tendinopathies (COL5A1, TNC, 
MMP3, GDF5), COL5A2 will also be discussed in this 
review because, like COL5A1, it codes for a protein which is 
a fundamental component of the Col V molecule (quaternary 
protein). Type I collagen (Col I), and its two coding genes 
COL1A1 and COL1A2, will also be discussed because it 
forms the major structural component of tendon, even 
though genetic variation has not yet been associated with 
tendinopathies or tendon properties. Associations have, 
however, been observed between genetic variation in 
COL1A1 and risk of ligament injury [43, 44]. 
 This article will review genes and proteins that are known to 
be related to tendon structure and/or the dynamic nature of 
tendon homeostasis, and the review will describe how variations 
within these genes may affect human tendon mechanical 
properties such as stiffness and elastic modulus. There is 
substantial evidence that tendon mechanical properties such as 
stiffness influence the capacity of the muscle-tendon unit to 
produce force during exercise of various kinds [4-8]. For 
example, it has been shown that a relatively stiffer muscle-
tendon unit is significantly related to maximal concentric and 
isometric muscle performance [4]. On the other hand, during 
cyclical contractions low tendon stiffness (high tendon 
compliance) has been shown to improve muscle power and 
efficiency [7]. Consequently, genotype associations with tendon 
mechanical properties are highly likely to also influence 
exercise performance in a more general sense. 
2. GENES AND PROTEINS OF INTEREST 
2.1. Collagen Type V 
2.1.1. Structure of Protein and Genes 
 Col V is a widely distributed quantitatively minor 
fibrillar collagen forming between 1-3% of total collagen 
content of tendon ECM [45], although evidence suggests that 
in functional terms it is a major collagen of developing 
connective tissues [46]. Col V can assemble into a diverse 
number of molecular forms but all contain a pro 1(V) chain. 
This pro 1(V) chain is encoded for by the COL5A1 gene 
(9q34.3) and comprises 66 exons distributed over 203.07 
kilobases (kb) of genomic DNA. There is a pro 2(V) chain 
which is encoded for by the COL5A2 gene (2q32.2), 
comprising of 54 exons and 147.98kb [47]. Together these 
chains form the heterotrimer protein structure of Col V 
([1(V)]22(V)), which is ubiquitous in human tendons. 
 
Table 1. Tendon Proteins, Genes of Focus, and Abbreviations Addressed in this Review 
 
Protein Abbreviation of Protein Used in this Review Genes of Focus in this Review Abbreviation of Gene of Focus 
Type V collagen Col V 
collagen, type V, alpha 1 
collagen, type V, alpha 2 
COL5A1 
COL5A2 
Tenascin C Ten C tenascin C TNC 
Matrix metalloproteinase-3 MMP-3 
matrix metallopeptidase 3  
(stromelysin 1, progelatinase) 
MMP3 
Growth/differentiation factor 5 GDF-5 growth differentiation factor 5 GDF5 
Type I collagen Col I 
collagen, type I, alpha 1 
collagen, type I, alpha 2 
COL1A1 
COL1A2 
Note: the two collagen proteins comprise numerous protein chains and therefore are dependent on more than one gene. 
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2.1.2. Function 
 Col V plays a functionally important role in tendon via 
its relationship with Col I fibrils, in that it is thought to co-
polymerise with Col I fibrils to form heterotypic fibres, and 
thereby organises and regulates the diameter of these fibres 
[48-51] as well as forming intermolecular cross-links with 
Col I fibrils [52]. Interaction of Col V with Col I in in vitro 
self-assembly assays has shown a decrease in the diameter of 
fibrils with increasing amounts of Col V [53], possibly due 
to an increase in nucleation sites in the thin filaments of Col 
V for a given quantity of Col I [49]. These sites serve as 
steric hindrances for the addition of Col I molecules, through 
amino terminal domains which project out, thereby 
regulating lateral growth and hence diameter [51, 52]. 
 Both fibril diameter [29, 54, 55] and extent of cross-
linking [56-59] are positively correlated with mechanical 
Table 2. Summary of Genetic Association Studies that have Identified a Polymorphic Association with Tendon 
Pathologies/Musculotendinous Range of Motion in Humans 
 
Gene Participants Gene Variant Phenotype Findings/Observations Study 
White Caucasian. 
72 with chronic ATP, 
39 with acute Achilles 
tendon rupture. 
129 control. 
 
Chronic 
ATP. 
Individuals with A2 (C) allele gene variant of 
this gene are less likely of developing 
symptoms of chronic Achilles tendinopathies 
Mokone et al., [39] 
White Caucasian. 
85 Australian and 93 
South African patients 
with ATP, respectively. 
210 Australian and 132 
South African control 
subjects. 
 
Individuals possessing ‘CC’ genotype had 
decreased risk of developing chronic ATP 
compared with those individuals with T allele 
(TC or TT genotypes) in both populations 
September et al., [38] 
White Caucasian. 
50 with chronic ATP, 
35 with acute Achilles 
tendon rupture. 
34 control. 
Standing leg 
raise, sit-
and-reach. 
Individuals with CT genotype were found to 
be less flexible than homozygous individuals 
Collins et al., [41] 
COL5A1 
White Caucasian. 
325 healthy and 
physically active 
cohort. 
Bst UI RFLP within 
3’ untranslated region 
(UTR) (rs12722 C/T) 
Sit-and-
reach. 
Older individuals (35 years) homozygous for 
the C allele showed greater flexibility 
Brown et al., [42] 
TNC 
White Caucasian. 
72 with chronic ATP, 
42 with acute Achilles 
tendon rupture. 
127 control 
GT dinucleotide 
repeat polymorphism 
within intron 17 
Chronic 
ATP. Acute 
Achilles 
tendon 
rupture. 
Individuals with 12 and 14 GT repeats appear 
to have 6-fold risk of developing Achilles 
tendon injuries. 13 and 17 repeats were 
underrepresented 
Mokone et al., [37] 
MMP3 
White Caucasian. 
75 with chronic ATP, 
39 with acute Achilles 
tendon rupture. 
(rs679620) A/G 
transition at 
nucleotide position 
28 within exon 2, 
(rs591058) T/C 
transition at 
nucleotide position 
1547 within intron 4, 
(rs650108) G/A 
transition at 
nucleotide position 
495 within intron 8. 
Chronic 
ATP. 
GG of rs679620, CC of rs591058, AA of 
rs650108 genotypes overrepresented in 
individuals with ATP but no association found 
independently with individuals with acute 
Achilles tendon rupture. 
Additional observation- inferred haplotype GC 
greater frequency in ATP, haplotype ATG 
greater in control subjects 
Raleigh et al., [40] 
GDF5 
White Caucasian. 
171 recruited. 
Australian population-
59 with chronic ATP. 
South African 
population-73 with 
chronic ATP, 39 with 
acute Achilles tendon 
rupture. 
Australian population-
142 control, South 
African population-96 
control. 
(rs143383) T/C 
substitution of 
functional promoter 
in 5’ UTR 
Chronic 
ATP. Acute 
Achilles 
tendon 
rupture. 
Individuals with TT genotype have twice the 
risk of developing both chronic ATP and acute 
Achilles tendon rupture 
Posthumus et al., [36] 
*ATP = Achilles Tendon Pathology. 
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properties of tendon such as stiffness and Young’s Modulus, 
in animal models. Additionally, this correlation has been 
reported in vivo in relation to fibril diameter in humans [55]. 
There appears to be an optimum level of permanent cross-
linking, above which there is a decrease in mechanical 
strength [53, 60, 61]. However, these studies investigated 
age-related declines in mechanical properties and the same 
relationship with cross-linking may not exist in a cross-
section of a younger population. Reduced Col V content has 
been reported to compromise the diameter of the collagen 
fibril in in vitro cultures [62, 63] and consequently may 
reduce the material properties of tendon such as maximum 
stress and linear modulus [53]. 
2.1.3. Evidence of Polymorphic Associations with Tendon 
Pathologies 
 The first study to report an association between variation 
in the COL5A1 gene and tendon pathology [39] identified 
the COL5A1 gene as an ideal candidate genetic marker of 
Achilles tendinopathies because it is on the same locus of 
genomic DNA as the ABO gene, which has been reported to 
be associated with tendon injuries in Hungarian and Finnish 
patients [64, 65]. Two restriction fragment length 
polymorphisms (RFLPs) were identified within the 3’ 
untranslated region (UTR) of the COL5A1 gene (BstUI and 
DpnII) that had no known role in the expression or function 
of Col V. An association was found between the BstUI 
RFLP (rs12722) and Achilles tendon pathology (ATP), and 
more specifically chronic tendinopathy without rupture (the 
C allele was protective against ATP). As the authors rightly 
stated, this association does not show conclusively that Col 
V is involved in the development of these pathologies, and it 
is of course likely that there are numerous genetic variants 
that contribute to the overall heritability of such conditions 
[66]. It is also possible that non-genetic factors influenced 
the results of the study described in this paragraph [39], as 
body mass and physical activity were not controlled 
participant selection criteria. 
 A subsequent study investigated the same variant of the 
COL5A1 gene but in two separate white populations in South 
Africa and Australia [38] and the results generally concurred 
with the initial association study [39], in that rs12722 (BstUI 
RFLP) within the 3’ UTR was associated with Achilles 
tendinopathies and associated with individuals who possess a 
‘T’ allele at this locus. Thus, individuals who were 
homozygous for the ‘C’ allele were apparently less likely to 
develop the condition. The authors intelligently attempted to 
investigate a combination of additional markers or 
neighbouring alleles in the same sequence region of the 3’ 
UTR of the COL5A1 gene, known as an ‘inferred’ haplotype, 
in order to provide more information as to the predisposing 
causative factor. The haplotype consisting of markers 
rs12722 and rs3196378 (alleles ‘T’ and ‘C’ respectively) was 
 
Fig. (1). Major microstructural components of tendons associated with tendon pathologies/musculotendinous range of motion, identifying 
related genes. * No genetic association with tendon pathologies/tendon properties yet reported, but its presence in this figure is warranted 
because it is the major structural component of tendon. Adapted from Collins and Raleigh (2009). 
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significantly overrepresented in the South African 
tendinopathy group but not in the Australian group. The 
DNA sequence that contains the ‘C’ allele at the rs3196378 
marker forms part of a miRNA recognition sequence. 
miRNA are key regulators of gene expression at a 
posttranscriptional level by inhibiting translation or inducing 
mRNA cleavage [67, 68]. Consequently, protein expression 
may be modified and in this instance one could speculate 
that COL5A1 expression may be altered, leading to 
suboptimal levels of Col V protein and ultimately a 
compromised collagen fibre and healing process. Regarding 
COL5A2, no polymorphisms as of yet have been associated 
with tendon pathologies or function. 
2.1.4. Possible Influences on Tendon Properties 
 Two recent studies considered a measurable in vivo 
phenotype that may link the COL5A1 gene variant to tendon 
injuries, by investigating flexibility - a possible immediate 
phenotype [41, 42]. Flexibility is an established determining 
factor for patellar tendinopathies in active populations [69, 
70]. Genetics has been reported to contribute substantially to 
the variability of certain flexibility phenotypes [71, 72], and 
although that is not the case in other studies [73, 74], 
associations between gene variants and flexibility are 
therefore plausible. COL5A1 was hypothesised to be 
associated with flexibility following reports that mutations in 
the COL5A1 gene have been implicated in Ehlers Danlos 
syndrome, a condition characterised by joint hypermobility 
[75]. These disease-associated rare mutations may produce 
non-functional COL5A1 and COL5A2 alleles leading to 
haploinsufficiency of COL5A1 and COL5A2 mRNA, 
predictably resulting in the synthesis of around half the 
amount of normal Col V protein [75-78]. Phenotypically, 
this may result in abnormally large collagen fibrils [79] and 
impaired mechanical properties of tendon. In the first study, 
an association was reported between the common 
polymorphism rs12722 and flexibility [41]. Individuals 
heterozygous (CT) for this genotype were less flexible than 
homozygous individuals of either allele, however the study 
sample contained significant heterogeneity in terms of 
tendon injury history - i.e. participants with tendinopathies, 
history of rupture, and no history of tendon injury were 
combined in the genotyping results. Furthermore, measures 
used to quantify flexibility, such as an instrumental standing 
leg raise [80] and a trunk flexion sit and reach test [81], are 
rather crude measures of the function of the muscle-tendon 
unit as a whole, and certainly do not provide precise data on 
the mechanical properties of the tendon per se. Regarding 
the instrumental standing leg raise test, subjectivity [82] and 
specifically the perception of pain onset, as well as abnormal 
defence reactions [83], could be particularly relevant to the 
participants with history of Achilles problems. However, the 
main critical comment on the instrumental standard leg raise 
test is that the measured phenotype is a composite of various 
factors including muscle and tendon stiffness and does not 
take into account the dimensions of the structures so the 
mechanical properties cannot be determined. Additionally, 
any kind of sit-and-reach test is a composite measure of 
various factors contributing to ‘flexibility’, including 
muscle-tendon unit stiffness [84], limb lengths and 
proportions [85]. Thus, we conclude that while their 
approach was a useful step in the study of the genetics of 
flexibility and range of motion, the mechanics of the tendon 
per se were clearly not determined by Collins et al., [41] so 
potential associations between tendon properties and genes 
coding for proteins expressed in tendon could not be 
investigated directly in that study. The previous critique is 
accentuated by a report showing the mechanical properties of 
the series elastic component (tendon-aponeurosis) are 
independent of the parallel elastic component (passive 
muscle stiffness) in vivo [86]. 
 In the second study, Brown et al., [42] investigated the 
COL5A1 rs12722 polymorphism and sit-and-reach 
performance in a healthy and physically active cohort (325 
Caucasian subjects). Individuals homozygous for the ‘C’ 
allele had greater flexibility, but this was only observed in 
the older (35 years) subjects where sex and COL5A1 
genotype accounted for approximately 23% of the variance. 
As per the previous study, some factors which may affect the 
material and mechanical properties of the tendon were not 
considered. For example, circulating oestrogen was not 
assessed in the female subjects - chronic oestrogen levels can 
influence tendon stiffness [87]. Also, a lack of detailed 
information regarding the habitual physical activity levels of 
the older subjects was another limitation noted by Brown et 
al., [42] themselves, because tendon stiffness can increase 
[15, 88] with higher physical activity and decrease [89, 90] 
with lower activity. 
 In conclusion for Col V, it is indeed possible that 
variations within the genes that encode for the molecular 
components of Col V may influence a tendon’s material and 
mechanical properties, although such gene variants have not 
yet been shown to influence tendon properties per se. Since 
Col V expression levels appear critical in determining a 
tendon’s fibre structure through diameter and cross-linking 
[52, 63], several testable hypotheses regarding genetic 
variants and mechanical properties of tendon such as 
stiffness, maximal strain and elastic modulus are likely to be 
tested in the coming years. 
2.2. Tenascin-C 
2.2.1. Structure of Protein and Gene 
 Ten C is an ECM glycoprotein consisting of 6 
monomers, expressed in tissues bearing high tensile stress, 
such as tendons and myotendinous and osteotendinous 
junctions [91] and as with the collagen fibre, is an important 
structural component of tendon [92, 93]. This protein is 
known to be sensitive to mechanical loading in vitro [94]. It 
is encoded by the TNC gene (9q33.1), which comprises 28 
exons spanning 97.63 kb of genomic DNA [47]. 
2.2.2. Function 
 Ten C is a structural component of tendons, yet is an 
elastic protein [95], and as it is expressed in mechanically 
loaded tendons it may contribute to increased elasticity of 
the ECM [92, 96, 97] via increased gene expression in 
response to stretch [98]. In addition to its structural roles, 
Ten C performs various regulatory roles within the ECM. 
Due to its modular structure, the protein is able to interact 
with various other proteins involved in ECM homeostasis, as 
well as playing an important role in regulating cell-matrix 
interactions [99]. It is also believed that Ten C plays an 
invaluable role in regulating proper alignment and 
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organisation of the collagen fibres in vitro [95]. Therefore, 
when Ten C is expressed it may contribute to an increased 
crimp angle - a region-specific morphological feature of 
collagen fibres associated with the mechanical properties of 
tendon. 
 Ten C may also be a strong candidate for involvement in 
the aetiology of musculoskeletal injuries, as expression of 
the TNC gene has shown to be altered with human 
tendinopathies, determined by immunoblotting [100, 101]. 
This may be particularly relevant when engaging in intensive 
activity following inactivity. Inactivity decreases tendon 
stiffness in vivo, particularly at the muscular end of human 
tendon [89]. Yet Ten C expression relies on mechanical 
loading and as it is an ‘elastic’ protein, a relative decrease in 
stiffness due to inactivity or insufficient mechanical loading 
makes intuitive sense if Ten C is more highly expressed. 
Indeed, the myotendinous interface has been reported to be 
mechanically the most vulnerable site for injury [102, 103]. 
Thus, during reloading after inactivity the overall 
extensibility (strain to failure) would decrease increasing the 
risk of tendon rupture, due to experiencing greater strains for 
a given load [104]. 
2.2.3. Evidence of Polymorphic Associations with Tendon 
Pathologies 
 One study investigated a guanine-thymine (GT) 
dinucleotide repeat polymorphism for potential association with 
the risk of incurring both chronic Achilles tendinopathies and 
Achilles tendon rupture [37]. This polymorphism is a tandem 
repeat, consisting of a 2 base pair sequence repeated a varying 
number of times within a non-coding region (intron 17). 
Variants containing 12 and 14 GT repeats were overrepresented 
in subjects with tendinopathies, while variants containing 13 
and 17 repeats were underrepresented. The control group had 
been active in high impact sports for a considerable time (11.5 
years) and were currently engaging in ~5 hours per week, and 
so their apparent resistance to tendinopathies was unlikely to be 
due to a significantly lower exposure to high impact loading. 
Thus, a genetic influence may indeed exist, although replication 
of these data would be a valuable development. Furthermore, 
whether the TNC polymorphism is involved in causative 
mechanisms is still debatable. 
2.2.4. Possible Influences on Tendon Properties 
 Even though the GT repeat polymorphism in intron 17 is 
not part of the coding sequence, intronic variations may 
influence the binding of proteins involved in gene 
transcription, thus affecting gene expression. As Ten C 
expression has been reported to be up-regulated in certain 
pathological conditions [105-107], it could be postulated that 
the 12 and 14 GT repeats within intron 17 of the TNC gene 
may overexpress Ten C, increasing the elastic properties of 
the myotendinous unit, as well as reducing the ultimate 
tendon strain to failure for a given load [97]. Thus, TNC is a 
candidate gene with regards to determining the degree of 
passive stiffness/compliance of tendon. 
2.3. Matrix Metalloproteinase 3 
2.3.1. Structure of Protein and Gene 
 MMP-3 (otherwise known as stromelysin-1) is part of a 
group of 5 domain structures of zinc-dependent enzymes 
known as Matrix Metalloproteinases (MMPs), characterised 
according to the type of zinc binding. Structurally, the 
MMP-3 protein constitutes a multi domain structure made up 
of a propeptide, a catalytic N-terminal domain and a 
haemopexin-like C-terminal, all of which combine to form 
functional MMP-3 which has the capacity to interact with its 
substrates [108]. The MMP-3 protein is encoded for by the 
MMP3 gene (11q22.2) which is 10 exons in length and 
covers 7.79kb [47]. 
2.3.2. Function 
 MMP-3 plays a crucial role in the normal development, 
repair and remodelling of connective tissues, and ultimately 
plays regulatory roles in maintaining ECM homeostasis, 
through proteolytic activity. This is achieved by catalysing 
the degradation of both ECM and non-ECM proteins [109-
111]. MMP-3 hydrolyses multiple substrates including 
different types of intact fibrillar collagens, proteoglycans and 
a wide range of ECM components [112]. The ECM is in a 
state of dynamic equilibrium between synthesis and 
degradation [113], and its gene expression has shown to be 
increased by mechanical loading in vitro [114, 115]. 
Recently, ECM regulation has been shown to be determined 
by a combination of duration and magnitude of the 
mechanical stimulus in vitro [13], and in an in vivo rodent 
model [116], which potentially represents the impact of 
differing forms of voluntary exercise on tissue remodelling 
processes in humans. 
 The expression level of MMP-3, which may be regulated 
at the transcriptional, translational, or posttranslational levels 
by interaction with inhibitors [117], appears to differ 
between normal and highly stressed tendons, as well as 
tendons displaying pathological characteristics, determined 
by histological analyses. In highly stressed tendons, 
expression levels are elevated compared to normal tendons 
in animal models [13, 118, 119], which is thought to 
represent a repair or maintenance function that may be 
associated with an underlying degenerative process [117]. In 
addition, ‘stress-shielding’ or load deprived tendon has 
shown to increase the expression of MMP-3 mRNA in 
relation to normal cadaveric tendon tissue samples, 
determined in vitro [118, 120, 121]. Collectively, these 
studies point toward a ‘U’ shape relationship between load 
and MMP-3 expression. The extremes of this relationship 
may cause a loss of mechanical function, which may be 
related to the subtle degradation of ECM components, 
notably those involved in cross-linking and/or stabilisation 
of the tendon structure [121], such as minor collagens 
including Col V as well as proteoglycans. 
 In contrast, a lower level of MMP-3 expression compared 
to normal tissue samples has been reported in human tendon 
displaying pathological characteristics [100, 117, 122-124]. 
These observations may represent a failure of the normal 
matrix remodelling process [125]. It should be noted that 
even in normal human tendon, there is a significant  
difference between sexes where males have twice the 
amount of resting mRNA expression levels of MMP-3 
compared to females [126], which may indicate an impaired 
ECM maintenance and a weakening of the material 
properties in females, leading to increased injury 
susceptibility [127]. 
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 Even though the evidence is generally consistent across 
studies, with regards to the MMP-3 gene expression in 
different mechanical environments and in pathologies, there 
are some complexities. For instance, increased MMP-3 
mRNA expression does not mean that a given amount of 
MMP-3 protein will be produced due to post-transcriptional 
and post-translational regulation [112, 125]. 
2.3.3. Evidence of Polymorphic Associations with Tendon 
Pathologies 
 Gene variants have been investigated in the MMP3 gene 
which have the potential to substantially alter its expression 
[128], particularly the 5A/6A polymorphism within the 
promoter region of human MMP3. This polymorphism has 
been associated with a number of pathological states [129-
131]. The association between gene variants in MMP3 and 
tendon pathology was first postulated when immunochemi-
cally detectable MMP-3 protein was lower in a ‘normal’ 
region of Achilles tendon tissue in patients with a degenerate 
core region nearby, compared to normal control tissue [100]. 
This suggests these patients with tendinosis were 
predisposed to developing the condition due to inherently 
reduced MMP-3 protein levels. 
 One study to date has reported an association between 
variation in the MMP3 gene and Achilles tendinopathy [40]. 
Three SNP’s spanning most of the gene were identified as 
being potentially informative, as they are part of all four 
major haplotypes within the MMP3 gene (one exon SNP - 
rs679620, two intron SNP’s - rs591058, rs650108). All three 
MMP3 variants were found to be associated with Achilles 
tendinopathy individually, and as inferred haplotypes - 
particularly between the rs679620 and rs591058 gene 
variants. These two variants were found to be in almost 
perfect linkage disequilibrium. In contrast, the ‘ATG’ 
inferred haplotype containing all three SNP’s were 
significantly underrepresented in the tendinopathy group 
compared to the control group, suggesting this combination 
has a protective effect against the development of Achilles 
tendinopathy. 
 Raleigh et al., [40] were the first to demonstrate an 
interaction between variants on two different genes, vis-à-vis 
the development of Achilles tendinopathy (all three SNP’s of 
the MMP3 gene and the marker rs12722 of the 3’ UTR 
region of COL5A1 gene). The rs679620 marker of the 
MMP3 gene and the rs12722 marker of the 3’ UTR region of 
COL5A1 gene represent the best pair of genotypes for 
estimating the risk for Achilles tendinopathy, with the ‘G+T’ 
allele combination associated with tendinopathies. However, 
the authors do not address how the MMP3 variants alone, or 
as haplotypes and inferred haplotypes between different 
genes, cause an increased/decreased risk of tendinopathies. 
Nevertheless, they do suggest that the rs679620 variant of 
MMP3, which is a non-synonymous polymorphism, may 
influence the downstream function of the mature MMP-3 
enzyme and its activation [129] due to the subtle change in 
the amino acid coding and its interaction with other amino 
acids (‘G’ allele=glutamate, ‘A’ allele=lysine). The ‘G’ 
allele may encourage elevated levels of MMP-3 expression 
via increased MMP-3 activation, as a result of altered 
interaction with other amino acids in the propeptide region. 
2.3.4. Possible Influences on Tendon Properties 
 As the COL5A1 BstUI RFLP was shown to be associated 
with human flexibility, the MMP3 rs679620 variant was 
investigated for this same association, though no association 
was evident [132]. The precise rationale for investigating a 
link between this gene variant and flexibility is unclear, 
although as a link was previously identified between the 
MMP3 gene variant and Achilles tendon injuries [40] and as 
flexibility has been reported to be a possible risk factor for 
these injuries [133], the investigation seems justified. It must 
be noted that the flexibility phenotype assessed was a 
measure of musculoskeletal passive flexibility, which 
encompasses tendons, ligaments, joint capsules, aponeuroses 
and fascia sheaths, as well as the muscle and not necessarily 
just the tendon. Thus, as previously mentioned in section 
2.1.4 there are limitations to the techniques used for 
measuring flexibility in these studies. 
 As the mechanical properties of tendons are primarily a 
function of the ECM, and because a majority of ECM 
components are substrates for the proteolytic activities of 
MMP-3 [109], it may be that MMP-3 expression would 
contribute to the material integrity, and thus tendon 
mechanical properties. It may be that elevated expression 
levels of the MMP3 gene indicate a degenerative 
environment, putting the ECM in a state of imbalance with a 
greater rate of degradation compared to synthesis. The 
tendon homeostatic abilities would thus be compromised and 
substrates involved in cross-linking and stabilisation of the 
collagen fibril (Col V) may be degraded, ultimately 
weakening the material properties and resulting in a 
reduction in matrix stiffness [56-57]. 
2.4. Growth Differentiation Factor-5 
2.4.1. Structure of Protein and Gene 
 GDF-5 is a member of the transforming growth factor 
(TGF) super-family, encoded for by the GDF5 gene 
(20q11.22) of which its entire coding region comprises 4 
exons and is approximately 21.42kb in length [47]. 
Structurally, it is a ‘dimer’ consisting of two monomers 
interlinked by disulfide bonds. Mature forms of the protein 
are approximately 110-140 amino acids in length and seven 
cysteine amino acid residues are involved in creating its rigid 
structure [134]. 
2.4.2. Function 
 GDF-5 is involved in maintenance, growth and repair of 
bones, cartilage and musculoskeletal soft tissues including 
tendon [135-137]. When GDF-5 was first investigated for its 
possible role in tendon biology, it was found to possess a 
unique ability to induce a tendon-like tissue rather than 
cartilage and bone, when implanted intra-muscularly in rats 
[138]. Further investigations found a significant role of 
GDF-5 in tendon within rodent models with induced 
Achilles tendon injuries. Firstly, GDF-5 was found to 
enhance tendon healing and tensile strength of the tendon 
when implanted on collagen sponges, in a dose-dependent 
manner [139]. Further studies examined the ultrastructural, 
compositional and mechanical characteristics of the Achilles 
tendon in rodents deficient in GDF-5, and found the 
maximum load to failure decreased possibly due to  
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significantly less collagen, an increase in irregularly shaped 
Col I fibrils and compromised material behaviour (decrease 
in strength and stiffness) [140-142]. Therefore 
unsurprisingly, GDF-5 has been shown to increase 
mechanical strength in these rodent models [143-146]. These 
studies are further supported at a cellular and gene level by 
studies showing an improved collagen organisation with 
GDF-5 treatment [147, 148], as well as an increased 
expression of genes and synthesis of the components of 
tendon ECM, in particular, Col I, Ten C and MMP-3 [149]. 
2.4.3. Evidence of Polymorphic Associations with Tendon 
Pathologies 
 The human GDF5 gene contains mutations known to 
cause a number of rare inherited disorders, including 
acromesomelic chondrodysplasia of the Hunter-Thompson 
and Grebe types as well as Du Pan Syndrome, all of which 
are characterised by musculoskeletal abnormalities, 
including shortened limb bones, brachydactyly and severe 
joint dislocations [150-152]. The hypothesised involvement 
of GDF5 in tendon pathologies derives from this evidence, 
as it was postulated that the observed joint dislocations may 
be attributed to abnormalities in tendons [140]. As well as 
genetic mutations within the GDF5 gene, a functional 
promoter SNP (rs143383; T/C) of the 5’ UTR of the GDF5 
gene has been associated with multifactorial disorders, such 
as osteoarthritis at different joint locations across different 
ethnic groups [153-156], congenital dislocation of the hip 
[157], as well as total body height, hip axis length and 
fracture risk [158, 159], and lumbar disc degeneration [160]. 
In articular cartilage of individuals with osteoarthritis, there 
was a 12% lower expression of GDF-5 associated with the 
‘T’ allele at this SNP marker compared to the ‘C’ allele 
[161]. So, a reduction in the expression of the GDF5 gene 
associated with the ‘T’ allele may contribute to tendon 
pathologies, and this has been investigated by one study. 
 In a case-control study, an association was reported 
between the GDF5 SNP rs143383 referred to above and the 
risk of ATP [36]. Individuals of ‘TT’ genotype were found 
to have approximately twice the risk of developing ATP 
within an Australian population independently and when 
combined with a South African population, which probably 
means it is less likely to be a false positive observation. No 
significant association between genotype and higher risk was 
shown in the South African cohort alone, although the 
observed odds ratio was still similar (~1.7). The relatively 
small sample size of the Australian tendinopathy group 
(n=59) as well as the different physical characteristics (body 
mass and BMI) between the ATP and control groups of both 
populations, are perhaps limitations of the study. However, 
the odds ratios and confidence intervals observed suggest a 
robust association and these findings complement those 
studies demonstrating the impact on gene expression of the 
GDF5 variant in question [161-163]. 
2.4.4. Possible Influences on Tendon Properties 
 It may be hypothesised that the material properties of the 
tendon are compromised in the presence of the rs143383 ‘T’ 
allele variant, i.e. a reduction in tensile strength and stiffness. 
GDF-5 may be involved in collagen cross-linking by 
promoting the proteolytic activation of lysyl oxidase [164] as 
well as mediating the collagen structure and organisation, by 
increasing the thickness of collagen fibrils [140]. Collagen  
cross-linking and diameter per se, have been shown to 
increase tendon matrix stiffness in animal models [54, 56, 
57] and humans [55], so the ‘T’ allele variant of GDF5 may 
hinder these processes and thus reduce tendon stiffness. 
Therefore, if gene variants within the GDF5 gene influence 
tendon material and mechanical properties, it is likely to be 
via mediating the growth of other structures, in particular 
Col I fibrils. 
2.5. Collagen Type 1 
2.5.1. Structure of Protein and Genes 
 Collagen is the main protein constituent of tendon tissue 
and is reported to make up 65-75% of a tendon’s dry mass 
[165] in cadaver tissue and more recently 90% of in vivo 
patella tendon biopsies in humans [166]. Collagen comprises 
fibrillar collagen molecules containing more than 95% Col I 
[27]. This collagen protein is encoded for by the COL1A1 
gene (17q21.33), which constitutes 52 exons and is 18.34kb 
in length, and to a lesser extent by the COL1A2 gene 
(7q21.3), which constitutes 52 exons also, and is 36.67kb in 
length [47]. The COL1A1 gene encodes for the alpha () 1 
chain, while the COL1A2 gene encodes for the  2 chain. 
Two  1 chains and one  2 chain combine to form a 
heterotrimer protein structure. 
2.5.2. Function 
 Col I is a major protein constituent contributing 
significantly to the structural integrity of soft tissues such as 
cruciate ligaments, joint capsules and tendons, via the 
formation of strong parallel bundles of fibres. Col I fibrils 
and fibres are well recognised to be involved in tensile 
strength and the stiffness of tendon matrix, based on its intra- 
and inter- molecular cross links, orientation, density, 
diameter and length, all of which have been shown to affect 
the mechanical properties of the tendon as a whole in animal 
models [54-59, 167, 168]. 
2.5.3. Possible Polymorphic Associations with Tendon 
Pathologies 
 Mutations as well as single nucleotide polymorphisms in 
the COL1A1 gene, particularly a SNP affecting the Sp1 
binding site in the first intron of the COL1A1 gene (+1245; 
G/T; rs1800012), have been associated with lower bone 
mineral density and osteoarthritis [169-176] as well as being 
implicated in the disease osteogenesis imperfecta (OI) which 
is characterised by fragile collagen structures [177-179]. 
Additionally, a point mutation in the COL1A2 gene 
(nucleotide position 1121) that substitutes serine or cysteine 
for glycine residues (C-to-T transition and G-to-T 
transversion, respectively), also leads to the OI phenotype 
[180]. Consequently, sequence variants such as these, and 
others that may have a less clinically evident but still 
important influence, might be associated with soft tissue 
injuries. Indeed, associations have been reported between 
SNP’s in the COL1A1 gene at the intronic Sp1 transcription 
factor binding site and the risk of cruciate ligament ruptures 
and shoulder dislocations [43, 44], as well as upper limb 
muscle strength in elderly men [175]. These associations 
may be mediated through reduced Col 1 content or a weaker 
form of Col 1, but as of yet no genetic association has been 
made with tendon pathologies or tendon properties. 
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2.5.4. Possible Influences on Tendon Properties 
 No association has yet been reported between variation in 
the COL1A1 gene and tendon pathologies or properties. It is 
known that a SNP within the intronic Sp1 binding site 
(rs1800012) increases transcriptional activity of the COL1A1 
gene, resulting in abnormal ratios of the 1(1) protein 
relative to 2(1), which possibly gives rise to weaker 
homotrimers being formed (three 1(1) chains) instead of the 
conventional heterotrimers (two 1(1) and one 2(1) chains) 
[178]. It has also been reported that two polymorphisms in 
the proximal promoter of COL1A1 are in linkage 
disequilibrium with the Sp1 polymorphism [181], and in fact 
form an extended haplotype with the Sp1 polymorphism to 
regulate COL1A1 transcription. This is achieved by affecting 
the binding affinity of important regulating factors, such as 
Sp1, with the ‘T’ allele at the Sp1 binding site found to have 
a higher DNA binding affinity than the ‘G’ allele [171]. 
Consequently, individuals who carry a ‘T’ allele instead of a 
‘G’ at this SNP, highly express COL1A1 and thus possess a 
greater proportion of the weaker 1 homotrimers, may be 
more likely to have a compromised tendon internal structure. 
It has also been suggested that overproduction of Col 1 1 
chains in tendon might result in a higher tensile strength 
[44], although that statement contradicts the mechanism just 
outlined and is not expanded upon by the authors. 
 It is unlikely that tendon properties are affected solely by 
the Sp1 polymorphism in intron 1 of the COL1A1 gene. It is 
more likely that the extended haplotype influences the 
transcription of COL1A1 [171] and the material quality of 
the Col I fibril, with individuals carrying a ‘T’ allele at the 
Sp1 polymorphism ultimately producing higher gene 
activity, which might contribute to a more adversely affected 
Col I fibril. In addition, other genes such as those already 
reviewed need to be considered at the same time. 
CONCLUSION 
 Referring to the studies examining gene variants and 
their associations with tendinopathies, it appears there is no 
single causative gene variant that predisposes individuals to 
tendinopathies. This suggests tendinopathies are likely to be 
polygenic. This concurs with the expectation that a multitude 
of genes, their associated proteins, and their heterogeneous 
interactions are required to maintain normal tendon structure 
and homeostasis through development, regeneration and 
normal function [62, 168]. Therefore, it is likely, even after 
controlling for other parameters such as gender, age and 
habitual physical activity, that the intrinsic material 
(structural and regulatory) and mechanical properties of a 
tendon, quite apart from tendinopathies, are similarly 
influenced by polygenics. 
 Caution must be taken when interpreting the findings of 
these genetic association studies on tendinopathies. 
Investigations into the genetic factors involved in their 
aetiology, thus far, are very much in their infancy [182]. To 
date, all studies examining the genetic factors involved in 
tendinopathies investigate the pathology of the Achilles 
tendon, so whether these findings are applicable to other 
types of tendon is unknown. Also, the studies fail to control 
for all pertinent environmental factors, which may influence 
inter-individual variability in risk of tendinopathy. Non-
genetic factors such as age, body mass and physical activity 
of participants, all of which may affect the risk of incurring 
tendon injuries (independent of genetic predisposition), are 
usually not controlled for when recruiting individuals for 
these studies. This is mainly because the studies are 
retrospective in nature, rather than prospective, in that the 
pathological condition was evident before genetic variables 
were considered. Lastly, these genotype-phenotype 
associations have only been reported in people of one form 
of geographic ancestry (white Caucasian), and it remains to 
be investigated whether these associations will be observed 
in peoples of other geographic ancestry. Additionally, to 
improve the strength of these relationships intra-ancestrally, 
it would be beneficial to conduct twin/family studies to 
provide estimated inter-individual variability that is 
inherited, which has not yet been done [182]. 
 Having further highlighted the role of ECM proteins and 
their possible link to tendinopathies, it appears they do not 
act as one single entity but subtly interact to form interlinked 
structures (Fig. 1) and govern dynamic processes within the 
ECM. Col V fibrils combine with Col I fibrils to regulate the 
diameter of the fibres [49] with Ten C playing an invaluable 
role in regulating the proper alignment and organisation of 
the collagen fibres [95]. MMP-3 may degrade minor 
collagens such as Col V, which may alter the cross-linking 
and stabilisation of the tendon structure [112]. And lastly, an 
improved collagen organisation and cross-linking density 
was observed with the addition of GDF-5 [147, 164]. The 
common theme in these associations is the integrity of the 
collagen fibre in conjunction with organisation, diameter and 
cross-linking, all of which have been linked to tendon 
properties such as tendon matrix stiffness [54, 183]. 
 It is therefore reasonable to suggest that variants in 
genomic DNA sequence within these and other relevant 
proteins are likely to contribute to observed phenotypic 
variations in the tendon, most notably the mechanical 
properties, which may have implications for physical 
performance capabilities and the risk of incurring 
musculoskeletal injuries. However, no study has yet 
attempted to investigate genetic influences upon tendon 
properties per se in an asymptomatic population. 
FUTURE 
 When investigating a gene variant’s influences on tendon 
properties, it is important to negate factors other than 
genetics that are likely to contribute to tendon phenotypes. 
To establish a valid and reliable association between a gene 
variant and tendon mechanical properties, experimental error 
must be minimised and appropriate phenotype measurements 
utilised, which has not been adequately achieved in the 
previous genetic association studies investigating flexibility 
[41, 42]. It would be more appropriate to measure the overall 
stiffness of the muscle-tendon unit to assess flexibility using, 
for example, passive isokinetic dorsiflexion adopted by 
Morse et al., [184] to assess the human gastrocnemius 
muscle-tendon unit. This comprehensive in vivo assessment 
utilises techniques such as dynamometry, electrogoniometry, 
electromyography (EMG) and ultrasonography. The 
mechanical properties of the tendon itself can be assessed in 
vivo, which would be in line with the objectives of 
associating genetics with tendon properties. A thorough and 
highly reliable assessment is detailed by Pearson and 
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Onambele [185] with respect to the tendon compliance of the 
patella tendon, in that dynamometry, EMG and 
ultrasonography were utilised as well as the force-
displacement relationship to calculate tendon mechanical 
stiffness. Therefore, an accurate, reproducible and non-
invasive assessment of tendon properties in vivo is required 
to maximise the ability to detect a genetic contribution to the 
interindividual variability in mechanical properties of human 
tendon. 
 From a genetic perspective, a powerful approach to find 
significant DNA polymorphisms associated with tendon 
phenotypes could be to perform genome-wide association 
studies (GWAS). Geneticists have developed genotyping 
arrays (often called SNP chips) that can now assay up to ~2 
million variants simultaneously which, due to linkage 
disequilibrium, capture a substantial proportion of total 
genomic variability [186]. GWAS involves testing a 
comprehensive catalogue of common genetic variants, and 
can be applied to a case-control study (to find those variants 
associated with a medical condition or other extreme 
phenotype, such as patients with tendinopathies or athletes 
successful in sports requiring high flexibility) or to a 
genotype-phenotype association study (to find those variants 
associated with a phenotype measured on a continuous 
scale). By testing all common variants, one could pinpoint 
key genes and shed light on underlying mechanisms. Three 
key results have emerged from GWAS: (1) most traits can be 
influenced by a large number of loci; (2) the vast majority of 
the common variants at these loci have a moderate effect, 
increasing risk by 10–50% (similar to effects of many 
environmental risk factors); and (3) the loci include most of 
the genes found by linkage analysis, but reveal many more 
genes not previously implicated [187]. Over the next decade, 
it would be desirable to conduct genetic studies of thousands 
of patients with tendinopathies (in case-control studies) and 
of healthy subjects with measures of flexibility (genotype-
phenotype studies), with appropriate combinations of GWAS 
and sequencing. In turn, intensive functional studies will be 
required to characterize the genes and pathways, and to 
construct animal models that mimic human tendon 
physiology. 
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